Literature DB >> 24534519

Transcranial Doppler to measure cerebral blood flow in delirium superimposed on dementia. A cohort study.

Gideon A Caplan1, ZhongZheng Lan2, Lyndal Newton3, Tasha Kvelde4, Catherine McVeigh3, Mark A Hill2.   

Abstract

OBJECTIVE: Delirium superimposed on dementia (DSD) is frequently not diagnosed, at great cost. Both delirium and dementia are associated with cerebral hypoperfusion. A switch to anaerobic glycolysis in the central nervous system during delirium compared to Alzheimer's dementia (AD) suggests greater hypoperfusion in DSD. The main aims of this study were to investigate whether cerebral hypoperfusion could differentiate DSD from related entities, and the characteristics of that hypoperfusion.
METHODS: Prospective cohort study of 44 Geriatric Medicine patients in 4 groups: (1) delirium, no history of dementia; (2) DSD; (3) acute illness without delirium or dementia; and (4) AD, no delirium. We measured CBF using transcranial Doppler to assess flow velocity (FV) and pulsatility index in the middle cerebral artery (MCA).
RESULTS: DSD has lower FV than either AD or delirium alone, or acute illness (28.2 ± 4.7 vs AD: 41.3 ±15.7; P = .040; vs delirium 37.7 ± 8.2; P =.009; vs acute illness 43.0 ± 8.3; P <.001). A mean MCA FV cut-off of 32.25 cm/s diagnoses DSD with a sensitivity of 0.875 and specificity of 0.788, area under the curve 0.884; P = .001. Resolution of delirium improves FV (P = .005). FV correlates with delirium severity (delirium index R = -0.39; P = .009) and dementia (Mini-Mental State Examination, R = 0.33; P = .029, and Informant Questionnaire on Cognitive Decline in the Elderly, R = -0.41; P = .005).
CONCLUSIONS: Transcranial Doppler is a potential diagnostic and monitoring test for DSD. Correlation with clinical indicators of delirium suggests pathophysiological significance. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Delirium; assessment of cognitive disorders/dementia; geriatric assessment; ultrasound

Mesh:

Year:  2014        PMID: 24534519     DOI: 10.1016/j.jamda.2013.12.079

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  6 in total

1.  2-18F-fluoro-2-deoxyglucose positron emission tomography in delirium.

Authors:  Lucy R Haggstrom; Julia A Nelson; Eva A Wegner; Gideon A Caplan
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-28       Impact factor: 6.200

2.  Use of Transcranial Doppler as a Biomarker of CAR T Cell-Related Neurotoxicity.

Authors:  Kathryn B Holroyd; Daniel B Rubin; Sarah LaRose; Andrew Monk; Sarah Nikiforow; Caron Jacobson; Henrikas Vaitkevicius
Journal:  Neurol Clin Pract       Date:  2022-02

3.  Carotid Plaque Strain Indices Were Correlated With Cognitive Performance in a Cohort With Advanced Atherosclerosis, and Traditional Doppler Measures Showed no Association.

Authors:  Carol C Mitchell; Stephanie M Wilbrand; Thomas D Cook; Nirvedh H Meshram; Catherine N Steffel; Rebecca Nye; Tomy Varghese; Bruce P Hermann; Robert J Dempsey
Journal:  J Ultrasound Med       Date:  2020-05-12       Impact factor: 2.153

Review 4.  Current Challenges in the Recognition and Management of Delirium Superimposed on Dementia.

Authors:  Anita Nitchingham; Gideon A Caplan
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-05       Impact factor: 2.570

5.  Dynamic cerebral autoregulation: A marker of post-operative delirium?

Authors:  Juliana R Caldas; Ronney B Panerai; Edson Bor-Seng-Shu; Graziela S R Ferreira; Ligia Camara; R H Passos; Marcelo de-Lima-Oliveira; Filomena R B G Galas; Juliano P Almeida; Ricardo C Nogueira; Natalia Mian; Fabio A Gaiotto; Thompson G Robinson; Ludhmila A Hajjar
Journal:  Clin Neurophysiol       Date:  2018-11-22       Impact factor: 3.708

Review 6.  The inter-relationship between delirium and dementia: the importance of delirium prevention.

Authors:  Tamara G Fong; Sharon K Inouye
Journal:  Nat Rev Neurol       Date:  2022-08-26       Impact factor: 44.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.